Phase 2 trial results support further development of neoadjuvant nivolumab-based CIT and adaptive de-escalation of CRT in patients with locoregionally advanced HNSCC, according to researchers.

Among patients with early-stage triple-negative breast cancer, a beneficial pathologic complete response rate was higher in ...

The study looked at patients with leukaemia, which occurs in bone marrow, and lymphoma, which affects the lymphatic system.

At 76 weeks, complete renal response rates were 46.4% with obinutuzumab and 33.1% with placebo. Serious adverse events were more common with obinutuzumab than placebo. Adding obinutuzumab to ...

A study published in The Lancet Haematology has reported a 73% response rate for CAR T-cell therapy among patients with certain blood cancers. The clinical trials were conducted by researchers ...